Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study.
Jason C HsuChen-Fang WeiSzu-Chun YangPeng-Chan LinYang-Cheng LeeChristine Y LuPublished in: BMJ open (2020)
Lung cancer survival rate increased and mortality decreased significantly following the launch of gefitinib and erlotinib in Taiwan.